Seres Therapeutics, Inc.

NASDAQ:MCRB

Biotechnology

Healthcare
$5.28 +1.70%

+$0.11 today

Market cap
$51.13M
Beta
0.11
P/E (TTM)
-1.3
EPS (TTM)
-$4.89
52W Low $5.31High $29.98

Volume 0.04M

Average 0.06M

MCRB Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Seres Therapeutics, Inc.NASDAQ: MCRB

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 9.58M shares rose 10.1% year over year, in line with the +10.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 8.2% from the prior quarter. Over 3 fiscal years it compounded at +17.9% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +10.1% toward the trailing-twelve-month pace of +10.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
9.58M+8.2% QoQ
Last fiscal yearDec 2025
8.86M+14.0% YoY
LTMMar 2026
8.99M+10.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.1%——
1 year+14.0%——
3-year CAGR+17.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
8.86M USD
Year-over-year change
+14.0%
4-year CAGR
+17.9%

Weighted Avg Shares vs competitors

How MCRB compares with its peers on the latest reported figures

  • MCRB's LTM Mar 2026 weighted avg shares of 8.99M shares is the lowest of the 9 companies compared; the peer median is 59.1M shares.
  • Its year-over-year change of +10.4% is the 6th highest of 9, against a peer median of +41.0%.
  • Over three fiscal years its annual growth of +17.9% compares with a peer median of +25.1%.
MCRB Competitors Peer median
Weighted Avg Shares for MCRB and competitors
Company Period LTM YoY 3-year CAGR
IRDOpus Genetics, Inc.LTM Mar 2026406.29M +1283.9%+214.9%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026312.72M +1040.7%+186.8%
CGTXCognition Therapeutics, Inc.LTM Mar 202679.93M +69.4%+35.9%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 202661.23M +1.8%+14.3%
SEERSeer, Inc.LTM Mar 202656.96M -7.5%-2.7%
SPROSpero Therapeutics, Inc.LTM Mar 202656.4M +3.7%+14.2%
HURATuHURA Biosciences, Inc.LTM Mar 202650.79M +127.0%+911.7%
ACTUActuate Therapeutics IncLTM Mar 202621.96M +12.5%+11.8%
MCRBSeres Therapeutics, Inc.LTM Mar 20268.99M +10.4%+17.9%
Peer median (excluding MCRB) 59.1M+41.0%+25.1%

Competitors are the stored peer set for MCRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue144.93M000789K
Cost of Revenue0019.34M3.53M4.13M
Gross Profit144.93M0(19.34M)(3.53M)(3.34M)
Gross Margin100.0%———-423.8%
Research & Development141.89M109.65M117.6M64.6M49.06M
Selling, General & Admin69.26M70.26M77.5M53.18M39.16M
Operating Expenses209.42M179.91M175.76M117.78M90.63M
Depreciation & Amortization5.95M6.63M6.24M5.47M4.13M
EBITDA(56.72M)(170.93M)(181.42M)(120.3M)9.83M
EBITDA Margin-39.1%———1245.8%
Operating Income(64.49M)(179.91M)(195.1M)(121.32M)(93.97M)
Operating Margin-44.5%———-11910.1%
Interest Income2.87M3.06M7.3M3.97M2.23M
Interest Expense2.91M6.02M13.18M00
Other Income / Expenses(1.09M)(3.67M)4.97M(4.46M)99.67M
Income Before Tax(65.58M)(183.58M)(190.13M)(125.77M)5.7M
Pre-Tax Margin-45.2%———721.9%
Income Tax Expense00000
Net Income(65.58M)(250.16M)(113.72M)(146.57M)5.7M
Net Margin-45.2%———721.9%
EPS (Basic)(14.30)(46.29)(17.77)(18.86)0.64
EPS (Diluted)(14.30)(46.29)(17.77)(18.86)0.64
Weighted Avg Shares4.59M5.4M6.4M7.77M8.86M
Weighted Avg Shares (Diluted)4.59M5.4M6.4M7.77M8.87M

Seres Therapeutics, Inc.

NASDAQ:MCRB

Intrinsic Alpha fair value

Locked

Current Price

$5.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.